Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 10/20 | 0.46 |
| ▸ | TTK | P33981 | 6/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.41 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.37 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539577 | 0.94 | PLK1 (0.48) | PLK1TTKRAD52PLK4GAK | |
| SCHEMBL30135828 | 0.91 | PLK1 (0.53) | PLK1TTKRAD52PLK4GAK | |
| SCHEMBL1203651 | 0.91 | PLK1 (0.53) | PLK1TTKRAD52PLK4GAK | |
| SCHEMBL3546382 | 0.91 | PLK1 (0.51) | PLK1TTKRAD52PLK4GAK | |
| SCHEMBL3537772 | 0.90 | PLK1 (0.52) | PLK1TTKRAD52PLK4GAK | |
| SCHEMBL1204276 | 0.88 | PRKDC (0.46) | PLK1TTKRAD52PLK4GAK | |
| SCHEMBL4080136 | 0.85 | PLK1 (0.42) | PLK1TTKRAD52PLK4GAK | |
| SCHEMBL4076255 | 0.82 | PLK1 (0.41) | PLK1TTKRAD52PLK4GAK | |
| SCHEMBL3542080 | 0.81 | PLK1 (0.40) | PLK1TTKRAD52PLK4GAK | |
| SCHEMBL2875624 | 0.81 | PRKDC (0.47) | PLK1TTKPLK4GAKSTK33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | PLK1 847/4885TTK 4453/4885RAD52 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.